Published in Circulation on June 30, 2003
Cell labeling with the positive MR contrast agent Gadofluorine M. Eur Radiol (2007) 1.32
Molecular imaging of inflammation in atherosclerosis. Theranostics (2013) 1.08
Targeted probes for cardiovascular MRI. Future Med Chem (2010) 1.02
Imaging approaches for the study of cell-based cardiac therapies. Nat Rev Cardiol (2009) 0.96
Increased neovascularization in advanced lipid-rich atherosclerotic lesions detected by gadofluorine-M-enhanced MRI: implications for plaque vulnerability. Circ Cardiovasc Imaging (2009) 0.91
In vivo detection of embryonic stem cell-derived cardiovascular progenitor cells using Cy3-labeled Gadofluorine M in murine myocardium. JACC Cardiovasc Imaging (2009) 0.90
MR-optical imaging of cardiovascular molecular targets. Basic Res Cardiol (2008) 0.89
Coronary computed tomography and magnetic resonance imaging. Curr Probl Cardiol (2009) 0.88
CMR assessment of endothelial damage and angiogenesis in porcine coronary arteries using gadofosveset. J Cardiovasc Magn Reson (2011) 0.87
Molecular imaging in cardiovascular magnetic resonance imaging: current perspective and future potential. Top Magn Reson Imaging (2008) 0.87
Gadofluorine M-enhanced MRI shows involvement of circumventricular organs in neuroinflammation. J Neuroinflammation (2010) 0.87
Comparison of gadofluorine-M and Gd-DTPA for noninvasive staging of atherosclerotic plaque stability using MRI. Circ Cardiovasc Imaging (2009) 0.86
MRI in guiding and assessing intramyocardial therapy. Eur Radiol (2005) 0.85
MRI-based biomechanical imaging: initial study on early plaque progression and vessel remodeling. Magn Reson Imaging (2009) 0.84
MRI for Crohn's Disease: Present and Future. Biomed Res Int (2015) 0.81
Molecular MRI of Inflammation in Atherosclerosis. Curr Cardiovasc Imaging Rep (2011) 0.81
Imaging biomarkers of cardiovascular disease. J Magn Reson Imaging (2010) 0.81
Contrast enhancement in atherosclerosis development in a mouse model: in vivo results at 2 Tesla. MAGMA (2004) 0.80
Imaging stem cell therapy for the treatment of peripheral arterial disease. Curr Vasc Pharmacol (2012) 0.80
Gadolinium-Based Contrast Agents for Vessel Wall Magnetic Resonance Imaging (MRI) of Atherosclerosis. Curr Cardiovasc Imaging Rep (2012) 0.79
Composite MR Contrast Agents for Conditional Cell-Labeling. Int J Imaging Syst Technol (2008) 0.79
Coronary magnetic resonance imaging: visualization of the vessel lumen and the vessel wall and molecular imaging of arteriothrombosis. Eur Radiol (2005) 0.79
In vivo MR imaging of plaque disruption and thrombus formation in an atherosclerotic rabbit model. Int J Cardiovasc Imaging (2011) 0.79
Molecular MRI of Atherosclerotic Plaque With Targeted Contrast Agents. Curr Cardiovasc Imaging Rep (2009) 0.77
Imaging Neuroinflammation - from Bench to Bedside. J Clin Cell Immunol (2014) 0.77
MRI in coronary artery disease. Eur Radiol (2004) 0.77
MR and Targeted Molecular MRI of Vulnerable Plaques. Interv Neurol (2013) 0.76
Magnetic resonance imaging of the pancreas in streptozotocin-induced diabetic rats: Gadofluorine P and Gd-DOTA. World J Gastroenterol (2015) 0.75
Non-invasive detection of vulnerable coronary plaque. World J Cardiol (2011) 0.75
Quantitative and qualitative estimation of atherosclerotic plaque burden in vivo at 7T MRI using Gadospin F in comparison to en face preparation evaluated in ApoE KO mice. PLoS One (2017) 0.75
Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol (2005) 5.60
Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA (2003) 3.45
A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol (2008) 2.40
Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol (2004) 2.23
VX2 carcinoma in rabbits after radiofrequency ablation: comparison of MR contrast agents for help in differentiating benign periablational enhancement from residual tumor. Radiology (2004) 2.14
Radiation exposure during cardiac CT: effective doses at multi-detector row CT and electron-beam CT. Radiology (2003) 2.07
Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med (2004) 1.91
Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology (2003) 1.90
Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol (2008) 1.85
Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology (2005) 1.79
MR colonography with barium-based fecal tagging: initial clinical experience. Radiology (2002) 1.67
Detection and characterization of intracardiac thrombi on MR imaging. AJR Am J Roentgenol (2002) 1.61
Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation (2004) 1.57
Evaluation of living liver donors with an all-inclusive 3D multi-detector row CT protocol. Radiology (2006) 1.55
Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol (2008) 1.55
To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med (2004) 1.51
Time-resolved three-dimensional MR imaging of gastric emptying modified by IV administration of erythromycin. AJR Am J Roentgenol (2003) 1.46
Peripheral vasculature: whole-body MR angiography with midfemoral venous compression--initial experience. Radiology (2004) 1.45
Tissue-specific MR contrast agents. Eur J Radiol (2003) 1.31
Imaging of myocardial perfusion with magnetic resonance. J Magn Reson Imaging (2004) 1.20
Inductively coupled stent antennas in MRI. Magn Reson Med (2002) 1.20
Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with Gadofluorine M. Contrast Media Mol Imaging (2007) 1.14
Whole-body MR imaging: evaluation of patients for metastases. Radiology (2004) 1.14
Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med (2002) 1.13
Detection of pulmonary nodules using a 2D HASTE MR sequence: comparison with MDCT. AJR Am J Roentgenol (2005) 1.11
Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits. Radiology (2002) 1.11
Positron emission tomography/computed tomography--imaging protocols, artifacts, and pitfalls. Mol Imaging Biol (2004) 1.07
Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging (2008) 1.05
"All-in-one" imaging protocols for the evaluation of potential living liver donors: comparison of magnetic resonance imaging and multidetector computed tomography. Liver Transpl (2005) 1.03
Imaging of myocardial infarction: comparison of magnevist and gadophrin-3 in rabbits. J Am Coll Cardiol (2002) 1.02
Interventional MRA using actively visualized catheters, TrueFISP, and real-time image fusion. Magn Reson Med (2003) 1.01
Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol (2011) 1.01
Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology (2004) 1.01
Antiangiogenic tumor treatment: early noninvasive monitoring with USPIO-enhanced MR imaging in mice. Radiology (2007) 1.00
Interstitial MR lymphography with MS-325: characterization of normal and tumor-invaded lymph nodes in a rabbit model. AJR Am J Roentgenol (2002) 1.00
Full-body cardiovascular and tumor MRI for early detection of disease: feasibility and initial experience in 298 subjects. AJR Am J Roentgenol (2005) 1.00
Potential living liver donors: evaluation with an all-in-one protocol with multi-detector row CT. Radiology (2002) 0.99
Whole-body 3D MR angiography of patients with peripheral arterial occlusive disease. AJR Am J Roentgenol (2004) 0.98
Assessment of ventricular function with single breath-hold real-time steady-state free precession cine MR imaging. AJR Am J Roentgenol (2002) 0.97
Comprehensive time-resolved MRI of peripheral vascular malformations. AJR Am J Roentgenol (2003) 0.95
Oral contrast agents for small bowel MRI: comparison of different additives to optimize bowel distension. Eur Radiol (2003) 0.95
Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol (2009) 0.95
MRI of the liver: can True FISP replace HASTE? J Magn Reson Imaging (2003) 0.95
HASTE MRI versus chest radiography in the detection of pulmonary nodules: comparison with MDCT. AJR Am J Roentgenol (2004) 0.95
Whole-body MRI using a rolling table platform for the detection of bone metastases. Eur Radiol (2002) 0.94
Early MR lymphography with gadofluorine M in rabbits. Radiology (2004) 0.93
First-pass and equilibrium-MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study. NMR Biomed (2004) 0.92
Healthcare costs for new technologies. Eur J Nucl Med Mol Imaging (2009) 0.92
Total-body 3D magnetic resonance angiography influences the management of patients with peripheral arterial occlusive disease. Eur Radiol (2005) 0.92
Ultrasmall superparamagnetic iron oxide-enhanced MR imaging of atherosclerotic plaque in hyperlipidemic rabbits. Acad Radiol (2002) 0.91
Visualization of swallowing using real-time TrueFISP MR fluoroscopy. Eur Radiol (2001) 0.91
Venous compression at high-spatial-resolution three-dimensional MR angiography of peripheral arteries. Radiology (2004) 0.91
Increased neovascularization in advanced lipid-rich atherosclerotic lesions detected by gadofluorine-M-enhanced MRI: implications for plaque vulnerability. Circ Cardiovasc Imaging (2009) 0.91
Three-dimensional volumetric interpolated breath-hold MR imaging for whole-body tumor staging in less than 15 minutes: a feasibility study. AJR Am J Roentgenol (2002) 0.90
Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med (2005) 0.90
Parallel acquisition techniques for accelerated volumetric interpolated breath-hold examination magnetic resonance imaging of the upper abdomen: assessment of image quality and lesion conspicuity. J Magn Reson Imaging (2005) 0.90
Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: preliminary experience. J Magn Reson Imaging (2003) 0.89
MR imaging of apparent small-bowel perfusion for diagnosing mesenteric ischemia: feasibility study. Radiology (2004) 0.89
Interventional MR angiography with a floating table. Radiology (2003) 0.88
Whole-body three-dimensional MR angiography with a rolling table platform: initial clinical experience. Radiology (2002) 0.87
Multidetector computed tomographic cholangiography in the evaluation of potential living liver donors. Transplantation (2002) 0.87
The potential of contrast-enhanced magnetic resonance imaging for predicting left ventricular remodeling. J Magn Reson Imaging (2002) 0.86
Assessment of myocardial viability using standard extracellular and necrosis specific MR contrast media. Acad Radiol (2002) 0.86
Myocardial perfusion and MR angiography of chest with SH U 555 C: results of placebo-controlled clinical phase i study. Radiology (2004) 0.86
Gadopentetate dimeglumine-enhanced three-dimensional MR-angiography: dosing, safety, and efficacy. J Magn Reson Imaging (2004) 0.85
Dose optimization of mannitol solution for small bowel distension in MRI. J Magn Reson Imaging (2004) 0.84
Detection of atherosclerosis: systemic imaging for systemic disease with whole-body three-dimensional MR angiography--initial experience. Radiology (2003) 0.84
Accentuation of high susceptibility of hypertrophied myocardium to ischemia: complementary assessment of Gadophrin-enhancement and left ventricular function with MRI. Magn Reson Med (2004) 0.84
Comparative studies on the efficacy of MRI contrast agents in MRA. Acad Radiol (2002) 0.83
Imaging-therapy computed tomography with quasi-monochromatic X-rays. Eur J Radiol (2008) 0.83
Assessment of normal, inflammatory, and tumor-bearing lymph nodes with contrast-enhanced interstitial magnetic resonance lymphography: preliminary results in rabbits. J Magn Reson Imaging (2003) 0.83
MR imaging of the vessel wall. Eur Radiol (2001) 0.82
MRI tumor characterization using Gd-GlyMe-DOTA-perfluorooctyl-mannose-conjugate (Gadofluorine M), a protein-avid contrast agent. Contrast Media Mol Imaging (2006) 0.82
Increased time rate of change of gradient fields: effect on peripheral nerve stimulation at clinical MR imaging. Radiology (2004) 0.82
Prediction of antiangiogenic treatment efficacy by iron oxide enhanced parametric magnetic resonance imaging. Invest Radiol (2007) 0.82
Coronary artery calcium score: influence of reconstruction interval at 16-detector row CT with retrospective electrocardiographic gating. Radiology (2004) 0.82
MR angiography of the chest. Radiol Clin North Am (2003) 0.82
Detection and quantification of breast tumor necrosis with MR imaging: value of the necrosis-avid contrast agent Gadophrin-3. Acad Radiol (2003) 0.81
Effect of field strengths on magnetic resonance angiography: comparison of an ultrasmall superparamagnetic iron oxide blood-pool contrast agent and gadopentetate dimeglumine in rabbits at 1.5 and 3.0 tesla. Invest Radiol (2006) 0.80
Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: safety and dialysability. AJR Am J Roentgenol (2002) 0.80
Colonography by magnetic resonance imaging. Eur J Gastroenterol Hepatol (2005) 0.80
Right-lobe living related liver transplantation: evaluation of a comprehensive magnetic resonance imaging protocol for assessing potential donors. Liver Transpl (2002) 0.79
Intraoperative radiation therapy in liver tissue in a pig model: monitoring with dual-modality PET/CT. Radiology (2004) 0.79
Contrast-enhanced MR imaging of postoperative scars and VX2 carcinoma in rabbits: comparison of macromolecular contrast agent and gadopentetate dimeglumine. Radiology (2003) 0.79
Gadofluorine-enhanced magnetic resonance imaging of carotid atherosclerosis in Yucatan miniswine. Invest Radiol (2006) 0.79
Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography. Invest Radiol (2003) 0.79
MR angiography for assessment of peripheral vascular disease. Radiol Clin North Am (2002) 0.79
Gadomer-17-enhanced 3D navigator-echo MR angiography of the pulmonary arteries in pigs. Eur Radiol (2001) 0.78
MR-based full-body preventative cardiovascular and tumor imaging: technique and preliminary experience. Eur Radiol (2004) 0.78
Magnetic resonance colonography with fecal tagging: an innovative approach without bowel cleansing. Top Magn Reson Imaging (2002) 0.78
Gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Invest Radiol (2002) 0.78
Dark lumen magnetic resonance colonography in a rodent polyp model: initial experience and demonstration of feasibility. Invest Radiol (2004) 0.78
Contrast-enhanced multidetector-CT cholangiography after living donor liver transplantation. Hepatogastroenterology (2007) 0.77
Synthesis of two 3,5-disubstituted sulfonamide catechol ligands and evaluation of their iron(III) complexes for use as MRI contrast agents. J Med Chem (2005) 0.77
MR angiography with a new rapid-clearance blood pool agent: Initial experience in rabbits. Magn Reson Med (2002) 0.77
Dynamic contrast-enhanced MR imaging of VX2 carcinomas after X-irradiation in rabbits: comparison of gadopentetate dimeglumine and a macromolecular contrast agent. Invest Radiol (2003) 0.77
New contrast media designed for x-ray energy subtraction imaging in digital mammography. Invest Radiol (2003) 0.76